Ligand Pharmaceuticals (LGND) Proxy Filing summary

Executive summary

• Annual meeting scheduled for June 6, 2025, to be held virtually, with voting on director elections, auditor ratification, and executive compensation approval.

• Business model centers on royalty-generating IP platforms, licensing, and investment in late-stage biopharma assets, with a focus on diversified revenue streams and low corporate cost structure.

• 2024 saw 28% royalty revenue growth and over 40% increase in core adjusted EPS, with $250M+ in cash, no debt, and a $125M credit facility.

• Major product milestones included FDA approvals for Ohtuvayre, Filspari, and Capvaxive, and the acquisition of Apeiron Biologics for Qarziba royalties.

• Strategic focus for 2025 includes new product launches, further investment in royalty assets, and continued operational efficiency.

Voting matters and shareholder proposals

• Proposals include electing eight directors, ratifying Ernst & Young LLP as auditor, and an advisory vote on executive compensation.

• Board recommends voting FOR all proposals.

• Voting is one share, one vote; directors elected by plurality, auditor ratification and say-on-pay require majority approval.

Board of directors and corporate governance

• Board comprises eight nominees, seven of whom are independent, with diverse backgrounds in life sciences, finance, and regulatory affairs.

• Board committees include Audit, Nominating and Corporate Governance, and Human Capital Management and Compensation, all with independent members.

• Board reviews environmental, social, and governance (ESG) initiatives and risk oversight.

• Directors receive a mix of cash and equity compensation, with updated award values for 2025 reflecting workload and market data.